The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase II study of cisplatin plus S-1 in patients with carcinomas of unknown primary site.
T. Kurata
No relevant relationships to disclose
A. Tsuya
No relevant relationships to disclose
A. Tamiya
No relevant relationships to disclose
I. Okamoto
Honoraria - Taiho Pharmaceutical
S. Ueda
No relevant relationships to disclose
N. Sugimoto
No relevant relationships to disclose
K. Matsumoto
No relevant relationships to disclose
I. Goto
No relevant relationships to disclose
M. Fukuoka
No relevant relationships to disclose
K. Nakagawa
Honoraria - Taiho Pharmaceutical